Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Receives $30.20 Average Price Target from Analysts

Shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) have received a consensus rating of “Moderate Buy” from the nine research firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $31.3333.

GLUE has been the subject of a number of recent research reports. Wells Fargo & Company increased their price objective on shares of Monte Rosa Therapeutics from $22.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, January 8th. Wedbush reiterated an “outperform” rating and set a $37.00 target price on shares of Monte Rosa Therapeutics in a report on Wednesday, January 7th. Guggenheim increased their price target on Monte Rosa Therapeutics from $16.00 to $34.00 and gave the company a “buy” rating in a research report on Thursday, January 8th. Jefferies Financial Group reaffirmed a “buy” rating and set a $31.00 price target on shares of Monte Rosa Therapeutics in a research report on Wednesday, January 7th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Monte Rosa Therapeutics in a research note on Monday, December 29th.

Insider Transactions at Monte Rosa Therapeutics

In other Monte Rosa Therapeutics news, CEO Markus Warmuth sold 5,466 shares of the stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $23.49, for a total value of $128,396.34. Following the completion of the sale, the chief executive officer owned 618,937 shares in the company, valued at $14,538,830.13. This trade represents a 0.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 6.90% of the company’s stock.

Institutional Investors Weigh In On Monte Rosa Therapeutics

Several hedge funds have recently bought and sold shares of GLUE. AQR Capital Management LLC increased its position in Monte Rosa Therapeutics by 459.4% during the second quarter. AQR Capital Management LLC now owns 1,283,942 shares of the company’s stock worth $5,791,000 after buying an additional 1,054,406 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Monte Rosa Therapeutics by 12.0% during the 2nd quarter. Geode Capital Management LLC now owns 1,124,160 shares of the company’s stock worth $5,071,000 after acquiring an additional 120,098 shares during the period. Marshall Wace LLP increased its holdings in shares of Monte Rosa Therapeutics by 102.4% during the 3rd quarter. Marshall Wace LLP now owns 902,834 shares of the company’s stock worth $6,690,000 after acquiring an additional 456,754 shares during the last quarter. Vestal Point Capital LP bought a new stake in Monte Rosa Therapeutics in the 3rd quarter valued at $5,928,000. Finally, Dimensional Fund Advisors LP raised its stake in Monte Rosa Therapeutics by 41.1% in the 3rd quarter. Dimensional Fund Advisors LP now owns 632,182 shares of the company’s stock valued at $4,684,000 after acquiring an additional 184,020 shares during the period. 79.96% of the stock is currently owned by institutional investors and hedge funds.

Monte Rosa Therapeutics Stock Up 0.1%

Shares of GLUE opened at $24.08 on Friday. Monte Rosa Therapeutics has a twelve month low of $3.50 and a twelve month high of $25.77. The stock has a market capitalization of $1.57 billion, a P/E ratio of 75.25 and a beta of 1.60. The company has a 50 day moving average of $16.94 and a 200-day moving average of $10.28.

Monte Rosa Therapeutics (NASDAQ:GLUE) last announced its earnings results on Thursday, November 6th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.06. The business had revenue of $12.77 million during the quarter, compared to analysts’ expectations of $7.37 million. Monte Rosa Therapeutics had a net margin of 11.54% and a return on equity of 8.28%. On average, sell-side analysts anticipate that Monte Rosa Therapeutics will post -1.49 earnings per share for the current fiscal year.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.